Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
Open Access
- 11 September 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 10 (5), R109-15
- https://doi.org/10.1186/ar2506
Abstract
No abstract availableThis publication has 45 references indexed in Scilit:
- Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosusAnnals Of The Rheumatic Diseases, 2008
- Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic EffectsToxicological Sciences, 2006
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLySThe Journal of Experimental Medicine, 2003
- Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune DiseasesImmunobiology, 2002
- Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILNature Immunology, 2002
- BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFFScience, 2001
- Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseasesArthritis & Rheumatism, 2001
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997